(PPHM, OWW, DSCO) CRWENewswire Stocks In Action
- 2011/12/07 05:34:35 投稿
- 再生数：7
- マイリスト数：0
Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients